KJCKorea
Journal Central

@article{ART002265450},
author={Jeong Chang-rok and LEE，JinWon and KO，Karam},
title={A Critical Study of the Arguments for and against a Moratorium on Glivec},
journal={Korean Journal of Medical Ethics },
issn={2005-8284},
year={2017},
volume={20},
number={3},
pages={257-275},
doi={10.35301/ksme.2017.20.3.257}

TY - JOUR
AU - Jeong Chang-rok
AU - LEE，JinWon
AU - KO，Karam
TI - A Critical Study of the Arguments for and against a Moratorium on Glivec
JO - Korean Journal of Medical Ethics
PY - 2017
VL - 20
IS - 3
PB - The Korean Society For Medical Ethics
SP - 257
EP - 275
SN - 2005-8284
AB - Glivec (Imatinib) is a medication used in the treatment of chronic myelogenous leukemia. This medication, which is manufactured by Norvatis, was licensed for prescription in South Korea in 2002. After being found guilty of providing illegal rebates to doctors who prescribe Glivec, Norvatis was fined by the Korean Ministry of Health. However, this incident has given rise to a debate concerning how exactly Norvatis should be penalized for its illegal actions. On the one hand, some argue that stiffer punishments should be issued, including a moratorium on the sale of Norvatis medication in Korea. On the other hand, some argue that such actions will unfairly punish leukemia patients rather than targeting the company itself. In this article, we examine the medical, pharmaceutical, and ethical arguments that can be given on both sides of this issue.
KW - Glivec and Generic;rebate two-out rule;moratorium on drugs;patient selection right;social justice;valuebased arguments
DO - 10.35301/ksme.2017.20.3.257
ER -

Jeong Chang-rok, LEE，JinWon and KO，Karam. (2017). A Critical Study of the Arguments for and against a Moratorium on Glivec. Korean Journal of Medical Ethics , 20(3), 257-275.

Jeong Chang-rok, LEE，JinWon and KO，Karam. 2017, "A Critical Study of the Arguments for and against a Moratorium on Glivec", Korean Journal of Medical Ethics , vol.20, no.3 pp.257-275. Available from: doi:10.35301/ksme.2017.20.3.257

Jeong Chang-rok, LEE，JinWon, KO，Karam "A Critical Study of the Arguments for and against a Moratorium on Glivec" Korean Journal of Medical Ethics 20.3 pp.257-275 (2017) : 257.

Jeong Chang-rok, LEE，JinWon, KO，Karam. A Critical Study of the Arguments for and against a Moratorium on Glivec. 2017; 20(3), 257-275. Available from: doi:10.35301/ksme.2017.20.3.257

Jeong Chang-rok, LEE，JinWon and KO，Karam. "A Critical Study of the Arguments for and against a Moratorium on Glivec" Korean Journal of Medical Ethics 20, no.3 (2017) : 257-275.doi: 10.35301/ksme.2017.20.3.257

Jeong Chang-rok; LEE，JinWon; KO，Karam. A Critical Study of the Arguments for and against a Moratorium on Glivec. Korean Journal of Medical Ethics , 20(3), 257-275. doi: 10.35301/ksme.2017.20.3.257

Jeong Chang-rok; LEE，JinWon; KO，Karam. A Critical Study of the Arguments for and against a Moratorium on Glivec. Korean Journal of Medical Ethics . 2017; 20(3) 257-275. doi: 10.35301/ksme.2017.20.3.257

Jeong Chang-rok, LEE，JinWon, KO，Karam. A Critical Study of the Arguments for and against a Moratorium on Glivec. 2017; 20(3), 257-275. Available from: doi:10.35301/ksme.2017.20.3.257

Jeong Chang-rok, LEE，JinWon and KO，Karam. "A Critical Study of the Arguments for and against a Moratorium on Glivec" Korean Journal of Medical Ethics 20, no.3 (2017) : 257-275.doi: 10.35301/ksme.2017.20.3.257